Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.55 |
| ▸ | LTA4H | P09960 | 5/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9968651 | 0.91 | HRH3 (0.54) | HRH3LTA4HKCNH2ESR2 | |
| Hydrochloric Acid SCHEMBL3588666 | 0.91 | HRH3 (0.53) | HRH3LTA4HKCNH2ESR2 | |
| SCHEMBL3592749 | 0.89 | MAPT (0.51) | HRH3LTA4HKCNH2NPC1RAB9A | |
| SCHEMBL3589168 | 0.88 | LTA4H (0.55) | HRH3LTA4HKCNH2 | |
| SCHEMBL3598019 | 0.85 | HRH3 (0.53) | HRH3LTA4HKCNH2ESR2 | |
| SCHEMBL3640202 | 0.78 | ACHE (0.51) | HRH3LTA4HKCNH2ESR2 | |
| SCHEMBL7134850 | 0.76 | LTA4H (0.69) | HRH3LTA4HMCHR1NPC1RAB9A | |
| SCHEMBL3591275 | 0.76 | ESR2 (0.58) | HRH3KCNH2NPC1RAB9AESR2 | |
| SCHEMBL3591758 | 0.76 | ESR2 (0.58) | HRH3KCNH2NPC1RAB9AESR2 | |
| SCHEMBL7139236 | 0.74 | LTA4H (0.89) | HRH3LTA4HNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963276-B9 | N-LINKED ARYL HETEROARYL INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS EHF (IS) | 2012-09-26 | — | — | EP | disclosed |
| EP-1963276-B9 | N-LINKED ARYL HETEROARYL INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS EHF (IS) | 2012-09-26 | — | — | EP | disclosed |
| EP-1963276-B1 | N-LINKED ARYL HETEROARYL INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS EHF (IS) | 2012-06-20 | — | — | EP | disclosed |
| EP-1963276-B1 | N-LINKED ARYL HETEROARYL INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS EHF (IS) | 2012-06-20 | — | — | EP | disclosed |
| US-7674802-B2 | leukotriene A4 hydrolase inhibitors; biaryl nitrogen-attached heterocycles | DECODE GENETICS, EHF (IS) | 2010-03-09 | — | — | US | disclosed |
| US-7674802-B2 | leukotriene A4 hydrolase inhibitors; biaryl nitrogen-attached heterocycles | DECODE GENETICS, EHF (IS) | 2010-03-09 | — | — | US | disclosed |
| US-7674802-B2 | leukotriene A4 hydrolase inhibitors; biaryl nitrogen-attached heterocycles | DECODE GENETICS, EHF (IS) | 2010-03-09 | — | — | US | disclosed |
| EP-1963276-A1 | N-LINKED ARYL HETEROARYL INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | Decode Genetics EHF (IS) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007073405-A1 | N-LINKED ARYL HETEROARYL INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS EHF (IS) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007073405-A1 | N-LINKED ARYL HETEROARYL INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS EHF (IS) | 2007-06-28 | — | — | WO | disclosed |
| US-20070142434-A1 | N-LINKED ARYL HETEROARYL INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE CHEMISTRY, INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070142434-A1 | N-LINKED ARYL HETEROARYL INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE CHEMISTRY, INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070142434-A1 | N-LINKED ARYL HETEROARYL INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE CHEMISTRY, INC. (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142434-A1 | N-LINKED ARYL HETEROARYL INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | LTA4H, LTB4R, LTC4S | HRH3 130/4885LTA4H 1/4885KCNH2 2827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.